The FDA’s Recent untitled letter to Pathway Genomics regarding their alleged direct-to-consumer marketing of the CancerInterceptTM Detect highlights the increased scrutiny facing lab-developed tests.

More information can be found here. The letter itself can be found here.

Coming Soon…

  • Quality Costs of Laboratory Information Management Systems
  • Insights into validation Open Source Software in a Regulated Environment